BS_42Y3YANN
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 75.82128777923784
- age_years
- 4.033
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.596
- IL6_JAK_STAT3_SIGNALING+0.572
- INFLAMMATORY_RESPONSE+0.539
- PROTEIN_SECRETION+0.524
- KRAS_SIGNALING_UP+0.510
- HYPOXIA+0.505
- TGF_BETA_SIGNALING+0.493
- INTERFERON_GAMMA_RESPONSE+0.479
- ALLOGRAFT_REJECTION+0.469
- INTERFERON_ALPHA_RESPONSE+0.468
Top 10 suppressed
- E2F_TARGETS-0.445
- G2M_CHECKPOINT-0.353
- MYC_TARGETS_V2-0.318
- DNA_REPAIR-0.259
- SPERMATOGENESIS-0.223
- MITOTIC_SPINDLE-0.106
- MYC_TARGETS_V1-0.073
- WNT_BETA_CATENIN_SIGNALING-0.072
- KRAS_SIGNALING_DN-0.053
- PANCREAS_BETA_CELLS-0.009
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_QRNSKFMS | pilocytic astrocytoma | — | 0.954 |
| 2 | BS_VW85Q4XJ | low-grade glioma | — | 0.954 |
| 3 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.946 |
| 4 | BS_HX0S30NE | pilocytic astrocytoma | — | 0.937 |
| 5 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.929 |
| 6 | BS_4A45GGSW | pilocytic astrocytoma | — | 0.928 |
| 7 | SRR6013590 | — | cohortA1 | 0.926 |
| 8 | BS_SDZY6RZ3 | pilocytic astrocytoma | — | 0.923 |
| 9 | BS_N1E0H8YQ | low-grade glioma | — | 0.923 |
| 10 | BS_FJWZ3M7V | low-grade glioma | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.596 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.572 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.539 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.524 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.510 | Inavolisib | — uncovered |
| HYPOXIA | 0.505 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.493 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.479 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.469 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.468 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.430 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.429 | Idelalisib | — uncovered |
| COMPLEMENT | 0.421 | Inavolisib | — uncovered |
| APOPTOSIS | 0.383 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.375 | Idelalisib | — uncovered |
| COAGULATION | 0.371 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.363 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.342 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.328 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.317 | Inavolisib | — uncovered |